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The development of increasingly immunocompromised mice has allowed for improved engraftment of human tissue in xenograft hosts. NOD/SCID IL2Rgamma-c null mice (NSG) represent the latest iterative attempt to limit both the innate and acquired immune function in mice, thus preventing immune surveillance during xenografting. NSG mice have severe T-and B-cell impairment, as well as a complete absence of natural killer-cells. 1, 2 Carroll and colleagues 3 have recently reported in Leukemia the engraftment of human acute myeloid leukemia cells in the bone marrow of NSG mice, suggesting that NSG mice may be more permissive to human malignant myeloid cell engraftment than the previous xenograft hosts. To date, there has been only limited success in establishing a robust xenograft model of low-risk myelodysplastic syndromes (MDS) despite the use of a variety of immune deficient and transgenic mice. In an attempt to improve on these models, we tested whether the increased deficiency in natural killer cell function in NSG mice might improve the myeloid cell engraftment of MDS samples with low myeloblast counts and provide a useful pre-clinical model of low-risk MDS. [4] [5] [6] [7] In all, 34 NSG mice were injected with unfractionated, T-cell depleted, or CD34 þ purified bone marrow cells from consented normal donors (three samples into 2-3 mice each), patients with acute myeloid leukemia (four samples into 1-2 mice each), or patients with MDS and bone marrow myeloblast counts ranging from 0-13% (five samples into 3-5 mice each) 24 h after recipient mice received 250 cGy total body irradiation ( Figure 1a ). All samples were previously cryopreserved, and engraftment was defined as 40.1% human CD45 þ cell infiltration, consistent with graft versus host disease (Figures 1d and e) .
We attempted to improve engraftment of human myeloid cells by injecting whole bone marrow cells intra-tibial (to abrogate potential trafficking/homing defects), by T-cell depleting-bone marrow samples (to limit the number of T cells that may contribute to graft versus host disease) and by injecting CD34 þ purified cells. Four out of five animals that received an intra-tibial injection of bone marrow cells died unexpectedly 40-56 days after injection (MDS samples 5, 6). The remaining intra-tibial injected mouse from MDS sample 6 had 0.12% peripheral blood human engraftment at 6 weeks (100% T-cells), suggesting that graft-versus-host disease may have contributed to the death of the other intra-tibial injected mice. Next, we retro-orbital injected T-cell depleted-bone marrow cells (42 log reduction in T cells) from MDS samples 5 and 6. Both samples had 0.2% human cell engraftment in the spleen, but no engraftment in the peripheral blood or bone marrow. Surprisingly, engrafted human cells were predominantly CD3 þ (70-80%), suggesting that T-cell expansion in NSG mice is robust even when less than 900 T cells were injected. Finally, we injected CD34 þ purified cells (autoMACS, Miltenyi, Auburn, CA, USA) from normal or MDS bone marrow cells. One mouse receiving normal CD34 þ bone marrow cells had 0.17% bone marrow engraftment, which consisted predominantly of B cells (95%). CD34 þ purified cells from three MDS samples (5, 6, 8) were injected retro-orbital, and only MDS sample 8 (13% myeloblasts) had human cell engraftment in the bone marrow (0.16, 17.7% of engrafted cells were CD33 þ following injection of 2 Â 10 6 cells) (Figures 1a and  b) . To ensure that the viability of CD34 þ injected cells was not compromised during the purification process; we assessed their growth in normoxic methylcellulose culture (H4544, Stem Cell Technologies, Vancouver, BC, Canada). CD34 þ purified cells from the normal bone marrow and MDS sample 8 produced 52 and 14 CFU per 1,000 cells plated, respectively. Interphase fluorescence in situ hybridization analysis from unfractionated and CD34 þ purified methylcellulose colonies from MDS sample 8 detected trisomy 8 in 190/200 and 188/200 cells, respectively, indicating that the CD34 þ purified cells were clonal. In contrast, CD34 þ cells from MDS samples 5 and 6 did not produce methylcellulose colonies, which may reflect the variable growth of MDS cells in normoxic vs hypoxic (3% oxygen) conditions. Collectively, these results indicate that intra-tibial injection, T-cell depletion or CD34 þ purification do not significantly improve the engraftment of low-blast count MDS samples in NSG mice.
In contrast to low-risk MDS cells, three human acute myeloid leukemia samples showed robust engraftment in the bone marrow of NSG mice (mean 1.6 vs 55.3%, respectively, Po0.0001), with the majority of engrafted acute myeloid leukemia cells being CD33 þ (60.5-98.5%). One mouse injected with a fourth acute myeloid leukemia sample died at day 35. This mouse had 10% human peripheral blood cell engraftment (100% T cells), suggesting graft-versus-host disease may have contributed to its death.
In summary, we were unable to establish a robust low-risk MDS xenograft model using NSG mice despite their profound immune deficiency. NSG mice had consistent CD3 þ cell engraftment/expansion with evidence of human CD3 þ cell organ infiltration in some mice. Our results highlight the challenges of creating a xenograft model of low-risk MDS and demonstrate that even small numbers of residual T-cells are capable of significant expansion in NSG mice leading to morbidity and mortality. Better, but still limited, success has been noted with MDS samples that contain increased blast counts (410%) and with the co-injection of MDS bone marrow cells with stromal cell lines. [4] [5] [6] [7] This suggests that clonal MDS cells may be dependent on cell extrinsic factors for survival, such as cell-cell interaction within the bone marrow niche and appropriate cytokine support. We suggest that future experiments evaluating the engraftment of low-risk MDS should focus on providing an appropriate microenvironment in NSG mice. This may include the addition of stromal cells and/or species specific cytokines, or the injection of cells into neonatal NSG mice. 8 
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